In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $39.25, changing hands for $39.41/share. When a stock ...

Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to include new pharmacodynamic data in Section 12.2. The ...

If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share... MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX ...

Myobloc, from Supernus Pharmaceuticals (SUPN), and Xeomin, from Merz Aesthetics — I concluded Revance may struggle to continue as a going concern, and would likely need to complete a stock split ...